These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11318816)

  • 1. Bactericidal activity of moxifloxacin against Staphylococcus aureus.
    Berrington AW; Perry JD; Gould FK
    Clin Microbiol Infect; 2001 Mar; 7(3):161-3. PubMed ID: 11318816
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
    Entenza JM; Que YA; Vouillamoz J; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3076-83. PubMed ID: 11600359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus.
    Schmitz FJ; Fluit AC; Lückefahr M; Engler B; Hofmann B; Verhoef J; Heinz HP; Hadding U; Jones ME
    J Antimicrob Chemother; 1998 Dec; 42(6):807-10. PubMed ID: 10052906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of albumin, globulin, pus and dead bacteria in aerobic and anaerobic conditions on the antibacterial activity of moxifloxacin, trovafloxacin and ciprofloxacin against Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli.
    Rubinstein E; Diamantstein L; Yoseph G; Gruzman G; Rubinovitch B; Barzilai A; Keller N
    Clin Microbiol Infect; 2000 Dec; 6(12):678-81. PubMed ID: 11284929
    [No Abstract]   [Full Text] [Related]  

  • 5. Intracellular activity of ciprofloxacin and moxifloxacin, a new 8-methoxyquinolone, against methicillin-resistant Staphylococcus aureus.
    Al-Nawas B; Shah PM
    J Antimicrob Chemother; 1998 Jun; 41(6):655-8. PubMed ID: 9687105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of and resistance to moxifloxacin in Staphylococcus aureus.
    Ince D; Zhang X; Hooper DC
    Antimicrob Agents Chemother; 2003 Apr; 47(4):1410-5. PubMed ID: 12654680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Staphylococcus aureus endocarditis using moxifloxacin.
    Berrington AW; Koerner RJ; Perry JD; Bain HH; Gould FK
    Int J Med Microbiol; 2001 Aug; 291(3):237-9. PubMed ID: 11554565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages.
    Seral C; Van Bambeke F; Tulkens PM
    Antimicrob Agents Chemother; 2003 Jul; 47(7):2283-92. PubMed ID: 12821480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of moxifloxacin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy.
    Tarasi A; Cassone M; Monaco M; Tarasi D; Pompeo ME; Venditti M
    J Chemother; 2003 Jun; 15(3):239-43. PubMed ID: 12868549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro activity of moxifloxacin combined with other antibacterials against methicillin-resistant Staphylococcus aureus.
    Maggiolo F; Capra R; Bottura P; Pravettoni G; Migliorino M; Suter F
    J Chemother; 2000 Jun; 12(3):195-8. PubMed ID: 10877512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro potency of moxifloxacin, clinafloxacin and sitafloxacin against 248 genetically defined clinical isolates of Staphylococcus aureus.
    Schmitz FJ; Fluit AC; Milatovic D; Verhoef J; Heinz HP; Brisse S
    J Antimicrob Chemother; 2000 Jul; 46(1):109-13. PubMed ID: 10882698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
    Presterl E; Mueller-Uri P; Grisold A; Georgopoulos A; Graninger W
    Eur J Clin Microbiol Infect Dis; 2001 Jul; 20(7):486-9. PubMed ID: 11561805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of trovafloxacin in experimental endocarditis caused by ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus.
    Kim YS; Liu Q; Chow LL; Chambers HF; Täuber MG
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3325-7. PubMed ID: 9835540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Resistance profiles to fluoroquinolones in clinical isolates of Gram positive cocci].
    Hidalgo M; Reyes J; Cárdenas AM; Díaz L; Rincón S; Vanegas N; Díaz PL; Castañeda E; Arias CA
    Biomedica; 2008 Jun; 28(2):284-94. PubMed ID: 18719726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus.
    Lemaire S; Tulkens PM; Van Bambeke F
    Antimicrob Agents Chemother; 2011 Feb; 55(2):649-58. PubMed ID: 21135179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.
    Pong A; Thomson KS; Moland ES; Chartrand SA; Sanders CC
    J Antimicrob Chemother; 1999 Nov; 44(5):621-7. PubMed ID: 10552978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux.
    Beyer R; Pestova E; Millichap JJ; Stosor V; Noskin GA; Peterson LR
    Antimicrob Agents Chemother; 2000 Mar; 44(3):798-801. PubMed ID: 10681364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model.
    Lister PD
    Clin Infect Dis; 2001 Mar; 32 Suppl 1():S33-8. PubMed ID: 11249827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I; Cars O
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus.
    Blondeau JM; Borsos S; Hesje CK
    J Chemother; 2007 Apr; 19(2):146-51. PubMed ID: 17434822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.